What is Saxenda?
Saxenda is liraglutide 3.0 mg, a once-daily subcutaneous GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and in pediatric patients aged 12 years and older with obesity, used as an adjunct to reduced-calorie diet and increased physical activity. 1
Mechanism of Action
Saxenda activates GLP-1 receptors, mimicking the effects of naturally occurring GLP-1. After eating, it acts on the hypothalamus to suppress appetite, delays gastric emptying, increases glucose-dependent insulin release, decreases glucagon secretion, and promotes pancreatic β-cell growth 2. This multi-pronged mechanism addresses both weight loss and metabolic dysfunction.
Clinical Efficacy
Liraglutide 3.0 mg produces clinically meaningful weight loss of approximately 8.0-8.4% at 56 weeks compared to 2.4-2.8% with placebo (difference of 5.4-5.6 kg) 2, 3. In the landmark SCALE trial of 3,731 non-diabetic patients:
- 63.2% of patients achieved ≥5% weight loss (vs 27.1% placebo)
- 33.1% achieved ≥10% weight loss (vs 10.6% placebo)
- Mean weight loss was 8.4 kg in the liraglutide group 3
The 2023 JAMA obesity guidelines position liraglutide as producing moderate weight loss (mean 8.0% at 56 weeks), which is less than semaglutide (14.9%) or tirzepatide (20.9%), but more than most other anti-obesity medications 2.
Dosing and Administration
Start at 0.6 mg subcutaneously once daily and escalate weekly by 0.6 mg increments until reaching the target dose of 3.0 mg daily 1. This gradual titration reduces gastrointestinal side effects. Inject in the abdomen, thigh, or upper arm at any time of day, regardless of meals. Rotate injection sites to reduce risk of cutaneous amyloidosis 1.
If more than 3 days elapse since the last dose, restart at 0.6 mg and re-escalate to minimize GI symptoms 1.
Guideline Recommendations
The 2022 AGA guidelines give a conditional recommendation (moderate quality evidence) for liraglutide 3.0 mg with lifestyle modifications in adults with obesity or overweight with weight-related complications 4. The conditional (rather than strong) recommendation reflects that while effective, liraglutide produces less weight loss than semaglutide, which may be prioritized for most patients 4.
The 2023 JAMA review recommends initiating anti-obesity medications in patients with inadequate response to lifestyle modifications, considering dual health benefits—for example, liraglutide improves both weight and glycemic control in patients with diabetes 2.
Additional Metabolic Benefits
Beyond weight loss, liraglutide improves:
- Waist circumference (mean reduction 3.22 cm) 5
- Blood pressure (reductions of 5.28-7.8 mmHg systolic) 6
- Lipid profiles 2
- Glycemic control in patients with prediabetes or diabetes 2
- Cardiovascular risk in meta-analyses 2
Adverse Effects and Safety
The most common adverse effects are gastrointestinal: nausea (8-44%), diarrhea (9-32%), vomiting (4-25%), and constipation (5-23%) 2, 6. These are typically mild-to-moderate and dose-dependent, improving with gradual titration 2, 7.
Critical Safety Warnings
Saxenda carries a boxed warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 1.
Additional warnings include:
- Acute pancreatitis: Discontinue if suspected 1
- Acute gallbladder disease: Monitor for cholelithiasis/cholecystitis 1
- Hypoglycemia: Risk when combined with insulin or sulfonylureas; dose reduction of these agents may be needed 2, 1
- Heart rate increase: Monitor regularly 1
- Renal impairment: Use caution, especially with dehydration from GI symptoms 1
- Suicidal ideation: Monitor and discontinue if symptoms develop 1
- Pregnancy: Contraindicated 1
Duration of Treatment
Saxenda must be used chronically for sustained benefit—weight regain occurs after discontinuation 2. In the STEP 4 trial, patients who stopped treatment after 20 weeks regained 6.9% of lost weight over 48 weeks 2. This underscores that obesity is a chronic disease requiring long-term pharmacotherapy.
Patient Selection
Appropriate candidates include 1:
- Adults: BMI ≥30 kg/m² OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
- Pediatric patients ≥12 years: Body weight >60 kg AND BMI corresponding to adult obesity cut-offs (≥30 kg/m²)
Limitations
- Do not combine with other liraglutide products or GLP-1 receptor agonists 1
- Safety not established in pediatric patients with type 2 diabetes 1
- Not studied in combination with other weight loss products 1
- Less effective than newer agents like semaglutide 2.4 mg or tirzepatide 2
Clinical Positioning
While semaglutide may be prioritized due to greater weight loss efficacy 4, liraglutide remains a valuable option due to its established safety profile, daily dosing flexibility, and widespread availability 2, 8. Real-world data from Portugal showed 85.8% of patients continued treatment long-term with mean weight loss of 7.6 kg (7.9%), with greater losses after 6 months of treatment 8.